Hexima Annual Financial Report for the year ended June 30 2017
Hexima Annual Financial Report for the year ended June 30 2017
Closing Share Price at 30 June 2017
Closing Share Price at 30 June 2017
Updated: Upcoming CEO Presentations
Shareholders are invited to attend a presentation by Hexima CEO Dr Nicole van der Weerden. To view a copy of the presentation click here.
Upcoming Event: Tuesday 25th July at 11.30am at Lvl 38, 88 Phillip Street Sydney (offices of Bell Potter).
Hexima Shareholder Update and Share Trading
Hexima is pleased to advise that it has completed a pivotal GLP repeat-dose dermal irritation study in minipigs for HPX124 which should provide sufficient pre-clinical animal toxicology data to support a first-in-human clinical trial for HXP124 as a treatment of onychomycosis. Further details are provided in the presentation.
Hexima commences research into application of plant defensin technology in Candidaemias and Candida-based biofilms
Hexima is pleased to announce the commencement of a project to assess the application of Hexima’s antifungal technology in control of medically important Candidaemias and Candida-based biofilms. Systemic Candida infections are a major problem in immunocompromised...
Hexima Rights Issue Completed
Dear Shareholders I am pleased to inform you that the Hexima Rights Issue successfully closed last week with an overall take-up through entitlements and oversubscriptions of 65.4%. This result was very encouraging and Hexima is grateful to all shareholders who...
Extension of Hexima’s rights issue offer
Hexima Limited ACN 079 319 314 (Company) wishes to advise shareholders that it is extending the invitation for shareholders to participate in the rights issue of 6 new shares for every 10 shares which shareholders held on the relevant record date (Offer), under the...
Hexima Interim Financial Report for the 6 Months Ended December 31 2016
Hexima Interim Financial Report 31 Dec 16
Hexima Prospectus Rights Issue
Hexima is pleased to offer each existing shareholder the opportunity to participate in a fully underwritten non-renounceable pro-rata offer to subscribe for 6 New Shares for every 10 Shares held on the Record Date to raise a maximum amount of $3,896,663 (before costs...
External Links
Take a look at these useful links to learn more about our industry.
